

Franc McCormick, Ph.D., F.R.S., D.Sc.

University of California, San Francisco (UCSF), USA



Frank McCormick, Ph.D., F.R.S., D.Sc. (Hon) is the Professor Emeritus of the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center. A native of Cambridge, England, Dr. McCormick received his B.Sc. in biochemistry from the University of Birmingham (1972) and his Ph.D. in biochemistry from the University of Cambridge (1975). Postdoctoral fellowships were held at the State University of New York at Stony Brook and in London at the Imperial Cancer Research Fund. He has been a Fellow of the Royal Society since 1996 and a Member of the National Academy of Sciences since 2014. Prior to joining the UCSF faculty, Dr. McCormick pursued cancer-related work at Cetus Corporation (Director of Molecular Biology, 1981-90; Vice President of Research, 1990-91) and Chiron Corporation, (Vice President of Research from 1991-92) and in 1992 he founded Onyx Pharmaceuticals and served as its Chief Scientific Officer until 1996. His group discovered and developed sorafenib and palbociclib, and pioneered cancer therapy using oncolytic viruses. His laboratory at UCSF focuses on functions of Ras proteins. More recently, he has taken a leadership role at the Frederick National Laboratory for Cancer Research, overseeing an NCI supported national effort to develop therapies against Ras-driven cancers.